COO

Cooper Companies presents a distinctive profile among medical device manufacturers, trading near the bottom of its 52-week range at $60.94 versus a high of $89.83, while maintaining steady operational performance. The current valuation at 2.83x trailing sales reflects a significant compression from historical levels, with the stock's 0.88 beta indicating lower volatility relative to broader market movements.

The fundamental screening highlights several noteworthy characteristics. Revenue growth of 5.69% year-over-year demonstrates consistent top-line expansion in the medical device sector, supported by a robust gross margin of 65.44%. This margin profile indicates substantial pricing power and manufacturing efficiency within COO's contact lens and surgical device segments. The operating margin of 17.19% translates to solid conversion of revenue into operational profitability, though the TTM P/E ratio of 29.28 suggests the market continues to price in future growth expectations despite the recent EPS contraction of 2.36%.

Strengths evident in systematic analysis include:

• Conservative balance sheet with a debt-to-equity ratio of just 0.3, providing meaningful financial flexibility
• Strong liquidity position reflected in the current ratio of 1.89
• Book value per share of $42.06 supporting a modest price-to-book multiple of 1.69

Risk factors flagged by the model include: Return metrics remain compressed with ROE at 4.83% and ROA at 3.24%, below typical medical device benchmarks. The negative EPS growth trajectory warrants monitoring alongside competitive positioning relative to peers MDLN and SOLV in the vision care market.